Abdul Raheem Thayyil
Research Subjects
Abdul Raheem Thayyil has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
J. Thimmasetty
Department of Pharmaceutics, Bapuji Pharmacy College, Davangere and Rajiv Gandhi University of Health Sciences, Bengaluru, India
2 shared publicationsAishwarya Hiremath
Department of Industrial Pharmacy, Bapuji Pharmacy College, SS layout, Shamnur Road, Davanagere 577004
1 shared publicationManjunath U Machale
Department of Pharmaceutics, Oxbridge College of Pharmacy, Bangalore 560091
1 shared publicationN. N. Shashank
Department of Pharmaceutics, Bapuji Pharmacy College, Davangere and Rajiv Gandhi University of Health Sciences Karnataka India
1 shared publication- N. N. Shashank
Department of Pharmaceutics, Bapuji Pharmacy College, Davanagere, Karnataka, India
1 shared publication N. Shashank Nayak
Department of Pharmaceutics, Bapuji Pharmacy College, Davangere and Rajiv Gandhi University of Health Sciences, Bengaluru, India
1 shared publication
Latest Publications
- Open Access
- 18 February 2020
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 10 (2) , 203-212
Pharmaceutical Co-Crystallization: Regulatory Aspects, Design, Characterization, and Applications
Pharmaceutical co-crystals are novel class of pharmaceutical substances, which possess an apparent probability of advancement of polished physical properties offering stable and patentable solid forms. These multi-component crystalline forms influence pertinent physicochemical parameters like solubility, dissolution rate, chemical stability, physical stability, etc. which in turn result in the materials with superior properties to those of the free drug. Co-crystallization is a process by which the molecular interactions can be altered to optimize the drug properties. Co-crystals comprise a multicomponent system of active pharmaceutical ingredient (API) with a stoichiometric amount of a pharmaceutically acceptable coformer incorporated in the crystal lattice. By manufacturing pharmaceutical co-crystals, the physicochemical properties of a drug can be improved thus multicomponent crystalline materials have received renewed interest in the current scenario due to the easy administration in the pharmaceutical industry. There is an immense amount of literature available on co-crystals. However, there is a lack of an exhaustive review on a selection of coformers and regulations on co-crystals. The review has made an attempt to bridge this gap. The review also describes the methods used to prepare co-crystals with their characterization. Brief description on the pharmaceutical applications of co-crystals has also been incorporated here. Efforts are made to include reported works on co-crystals, which further help to understand the concept of co-crystals in depth.
- 18 February 2020
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 10 (2) , 203-212
Open AccessPharmaceutical Co-Crystallization: Regulatory Aspects, Design, Characterization, and Applications
Pharmaceutical co-crystals are novel class of pharmaceutical substances, which possess an apparent probability of advancement of polished physical properties offering stable and patentable solid forms. These multi-component crystalline forms influence pertinent physicochemical parameters like solubility, dissolution rate, chemical stability, physical stability, etc. which in turn result in the materials with superior properties to those of the free drug. Co-crystallization is a process by which the molecular interactions can be altered to optimize the drug properties. Co-crystals comprise a multicomponent system of active pharmaceutical ingredient (API) with a stoichiometric amount of a pharmaceutically acceptable coformer incorporated in the crystal lattice. By manufacturing pharmaceutical co-crystals, the physicochemical properties of a drug can be improved thus multicomponent crystalline materials have received renewed interest in the current scenario due to the easy administration in the pharmaceutical industry. There is an immense amount of literature available on co-crystals. However, there is a lack of an exhaustive review on a selection of coformers and regulations on co-crystals. The review has made an attempt to bridge this gap. The review also describes the methods used to prepare co-crystals with their characterization. Brief description on the pharmaceutical applications of co-crystals has also been incorporated here. Efforts are made to include reported works on co-crystals, which further help to understand the concept of co-crystals in depth.
- 29 January 2020
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 16 (1) , 160-169
Oral Bioavailability Enhancement of Paliperidone by the use of Cocrystalization and Precipitation Inhibition
- 29 January 2020
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 16 (1) , 160-169
Oral Bioavailability Enhancement of Paliperidone by the use of Cocrystalization and Precipitation Inhibition
- 19 November 2019
- Published by Royal Society of Chemistry (RSC)
- p. 170-173
Solid State Manipulation of Paliperidone for Its Bioavailability Enhancement Using Precipitation Inhibitors
The discovery of new drug molecules, which belongs to BCS class II and class IV, are suffering from poor aqueous solubility related issues. Pharmaceutical scientists are seeking various approaches such as polymorphism, cocrystals, salt formation, etc. to overcome these issues. Among the various methods, modifications of drugs into pharmaceutically useful cocrystals using coformers have been emerged in recent years. This improves the physicochemical properties such as solubility, dissolution, stability, and bioavailability. In addition to this, precipitation inhibitor (PPI) such as hydroxy propyl methyl cellulose (HPMC) can provide a ‘parachute’ effect in biological medium, which further improves the bioavailability of the drug by preventing its precipitation upon the dissociation of cocrystals. Selection of coformers, from the Generally Recognized As Safe (GRAS) list by FDA, can be done by predicting the cocrystal formation using the Hansen solubility parameter (HSP).
- 19 November 2019
- Published by Royal Society of Chemistry (RSC)
- p. 170-173
Solid State Manipulation of Paliperidone for Its Bioavailability Enhancement Using Precipitation Inhibitors
The discovery of new drug molecules, which belongs to BCS class II and class IV, are suffering from poor aqueous solubility related issues. Pharmaceutical scientists are seeking various approaches such as polymorphism, cocrystals, salt formation, etc. to overcome these issues. Among the various methods, modifications of drugs into pharmaceutically useful cocrystals using coformers have been emerged in recent years. This improves the physicochemical properties such as solubility, dissolution, stability, and bioavailability. In addition to this, precipitation inhibitor (PPI) such as hydroxy propyl methyl cellulose (HPMC) can provide a ‘parachute’ effect in biological medium, which further improves the bioavailability of the drug by preventing its precipitation upon the dissociation of cocrystals. Selection of coformers, from the Generally Recognized As Safe (GRAS) list by FDA, can be done by predicting the cocrystal formation using the Hansen solubility parameter (HSP).
- Open Access
- 14 October 2019
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 222-228
FORMULATION AND OPTIMIZATION OF LEVAMISOLE CHEWABLE TABLETS
Objective: The aim of the present study was to prepare and optimize levamisole chewable tablets by using various super disintegrants, namely; sodium starch glycolate, DRC Indion 204, and DRC Indion 234. Methods: Drug excipient compatibility study was carried out by FTIR spectroscopy to verify the compatibility of levamisole with the excipients. Nine batches of levamisole chewable tablets were prepared according to 32 factorial designs using a direct compression method by optimizing the super disintegrant concentration. The powder blend was exposed to pre-compression studies of the powder blend followed by post-compression studies of the formulated tablets. Results: FTIR study revealed that the excipients used in the formulations were compatible with the drug. The pre-compression and post-compression parameters were found within the IP limits. Form the dissolution studies, it was evident that the formulation prepared with DRC Indion 234 (50 mg) showed maximum percentage drug release in 45 min (97.13%) hence it is considered as optimized formulation. When compared to all other formulation, the batches with DRC Indion 234 (F7-F9) showed a better release of the drug (90 % drug release within 45 min). Conclusion: Nine batches of levamisole chewable tablets were successfully formulated by optimizing the concentration of super disintegrants such as sodium starch glycolate, DRC Indion 204, and DRC Indion 234. It was concluded from the dissolution studies that the DRC Indion 234 is the best super disintegrant irrespective of their concentration for the formulation of levamisole chewable tablets when compared to sodium starch Glycolate and DRC Indion 204.
- 14 October 2019
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 222-228
Open AccessFORMULATION AND OPTIMIZATION OF LEVAMISOLE CHEWABLE TABLETS
Objective: The aim of the present study was to prepare and optimize levamisole chewable tablets by using various super disintegrants, namely; sodium starch glycolate, DRC Indion 204, and DRC Indion 234. Methods: Drug excipient compatibility study was carried out by FTIR spectroscopy to verify the compatibility of levamisole with the excipients. Nine batches of levamisole chewable tablets were prepared according to 32 factorial designs using a direct compression method by optimizing the super disintegrant concentration. The powder blend was exposed to pre-compression studies of the powder blend followed by post-compression studies of the formulated tablets. Results: FTIR study revealed that the excipients used in the formulations were compatible with the drug. The pre-compression and post-compression parameters were found within the IP limits. Form the dissolution studies, it was evident that the formulation prepared with DRC Indion 234 (50 mg) showed maximum percentage drug release in 45 min (97.13%) hence it is considered as optimized formulation. When compared to all other formulation, the batches with DRC Indion 234 (F7-F9) showed a better release of the drug (90 % drug release within 45 min). Conclusion: Nine batches of levamisole chewable tablets were successfully formulated by optimizing the concentration of super disintegrants such as sodium starch glycolate, DRC Indion 204, and DRC Indion 234. It was concluded from the dissolution studies that the DRC Indion 234 is the best super disintegrant irrespective of their concentration for the formulation of levamisole chewable tablets when compared to sodium starch Glycolate and DRC Indion 204.
- Open Access
- 30 July 2019
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Pharmacy and Pharmaceutical Sciences
- p. 57-64
FORMULATION AND COMPARATIVE EVALUATION OF ONDANSETRON HYDROCHLORIDE MOUTH DISSOLVING TABLETS IN INDIA
Objective: The aim of the present study was to prepare the ondansetron hydrochloride Mouth Dissolving Tablets (MDTs) followed by its comparison with ethical and non-ethical (generic) marketed tablets. Methods: Prior to the formulation, drug excipient compatibility study was carried out by FTIR spectroscopy. The λmax was determined by UV spectroscopy. The ondansetron hydrochloride MDTs were prepared by direct compression method using Sodium Starch Glycolate (SSG) as super disintegrant and camphor as a sublimating agent. Then the prepared MDTs were subjected to evaluation of post compression parameters such as thickness and diameter, weight variation, wetting time, hardness, friability, disintegration and dissolution. The results obtained were compared with that of ethical and non-ethical marketed ondansetron hydrochloride 4 mg tablets. Results: The λmax was found at 310 nm. FTIR study revealed that excipients used in the prepared formulations are compatible with the drug. The thickness and diameter was in the range of 2.646 to 3.27 mm and 6.0 to 8.12 mm, respectively. Friability was in the range of 0.43 to 0.88 % and had a slightly higher friability (1.27%) for sublimated tablets. Wetting time and disintegration time were in the range of 15 to 40 sec and 23 to 50 sec, respectively. The 100 % drug release was found within 180 sec for all the codes. These results were then compared with non-ethical film coated ondansetron marketed tablets. Conclusion: Ondansetron hydrochloride MDT 4 mg tablets prepared in the laboratory were under specified IP limits. The experimental findings demonstrated that any of these ethical and non-ethical tablets of ondansetron hydrochloride can be selected, advised by the physician or pharmacist, as per the patient’s need and economical status.
- 30 July 2019
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Pharmacy and Pharmaceutical Sciences
- p. 57-64
Open AccessFORMULATION AND COMPARATIVE EVALUATION OF ONDANSETRON HYDROCHLORIDE MOUTH DISSOLVING TABLETS IN INDIA
Objective: The aim of the present study was to prepare the ondansetron hydrochloride Mouth Dissolving Tablets (MDTs) followed by its comparison with ethical and non-ethical (generic) marketed tablets. Methods: Prior to the formulation, drug excipient compatibility study was carried out by FTIR spectroscopy. The λmax was determined by UV spectroscopy. The ondansetron hydrochloride MDTs were prepared by direct compression method using Sodium Starch Glycolate (SSG) as super disintegrant and camphor as a sublimating agent. Then the prepared MDTs were subjected to evaluation of post compression parameters such as thickness and diameter, weight variation, wetting time, hardness, friability, disintegration and dissolution. The results obtained were compared with that of ethical and non-ethical marketed ondansetron hydrochloride 4 mg tablets. Results: The λmax was found at 310 nm. FTIR study revealed that excipients used in the prepared formulations are compatible with the drug. The thickness and diameter was in the range of 2.646 to 3.27 mm and 6.0 to 8.12 mm, respectively. Friability was in the range of 0.43 to 0.88 % and had a slightly higher friability (1.27%) for sublimated tablets. Wetting time and disintegration time were in the range of 15 to 40 sec and 23 to 50 sec, respectively. The 100 % drug release was found within 180 sec for all the codes. These results were then compared with non-ethical film coated ondansetron marketed tablets. Conclusion: Ondansetron hydrochloride MDT 4 mg tablets prepared in the laboratory were under specified IP limits. The experimental findings demonstrated that any of these ethical and non-ethical tablets of ondansetron hydrochloride can be selected, advised by the physician or pharmacist, as per the patient’s need and economical status.